Gene Therapy Reaches XLRS Milestone
Atsena Therapeutics reports positive interim data for XLRS gene therapy
Clinical Scorecard: Gene Therapy Reaches XLRS Milestone
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Primarily affects males, diagnosed in childhood. |
| Care Setting | |
Key Highlights
- Structural and functional improvements observed in treated adults.
- Foveal schisis closure confirmed in treated adults.
- Enrollment underway for Part C of the trial.
Guideline-Based Recommendations
Diagnosis
Management
- ATSN-201 is being evaluated as a gene therapy treatment option.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Safety findings in pediatric patients consistent with adults.
Clinical Best Practices
- Monitor for foveal schisis closure in treated patients.
- Utilize microperimetry and OCT for assessing treatment outcomes.
Related Resources & Content
